CytRx was recently featured in an article by Seeking Alpha contributor John Mylant, who dubbed the small-cap biotech company a “diamond in the rough.” Mylant highlights clinical studies that demonstrate the potential of CytRx’ improved version of standard of care chemotherapy agent, doxorubicin.
While CytRx’ formulation, aldoxorubicin, has yet to generate revenues, Mylant echoes agreement with the company’s management that the drug candidate has the potential to replace the widely used doxorubicin and create a “huge” revenue stream.
Mylant evidenced his sentiment by pointing to results from CytRx, in which the company reported best response for the 13 evaluable soft tissue sarcoma trial subjects:
• Five (38.5%) achieved partial response, as defined as tumor shrinkage of more than 30%;
• Seven (53.8%) showed prolonged stable disease (defined as tumor shrinkage <30% from baseline or tumor growth <20% from the nadir);
• Eight (61.5%) had tumor shrinkage;
• Five of eight patients (62.5%) who demonstrated either partial responses or prolonged stable disease after treatment with aldoxorubicin had been previously treated with doxorubicin and had failed to respond.
Results from top-line data for the global phase 2B clinical trials, designed to measure the progression-free survival, tumor response, and overall survival of patients with advanced soft tissue sarcomas treated with aldoxorubicin, are expected in December 2013.
“It appears aldoxorubicin has the potential to place a very strong foothold in the oncology market. It makes sense the way CytRx is researching and presenting this alternative drug to a market that already exists,” wrote Mylant, in discussing the superiority of the drug candidate.
To read Mylant’s article in its entirety visit http://seekingalpha.com/article/1734522
For more information on CytRx, visit www.CytRx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
